Analyzing Cytocore (OTCMKTS:MDIT) and Merit Medical Systems (OTCMKTS:MMSI)
Cytocore (OTCMKTS:MDIT) and Merit Medical Systems (NASDAQ:MMSI) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, dividends, institutional ownership, risk and earnings.
Insider and Institutional Ownership
97.7% of Merit Medical Systems shares are held by institutional investors. 85.4% of Cytocore shares are held by company insiders. Comparatively, 4.8% of Merit Medical Systems shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Cytocore has a beta of 3.32, meaning that its share price is 232% more volatile than the S&P 500. Comparatively, Merit Medical Systems has a beta of 1.1, meaning that its share price is 10% more volatile than the S&P 500.
This table compares Cytocore and Merit Medical Systems’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Merit Medical Systems||4.68%||10.99%||6.50%|
Earnings and Valuation
This table compares Cytocore and Merit Medical Systems’ revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Cytocore||$6.81 million||0.51||-$6.81 million||N/A||N/A|
|Merit Medical Systems||$882.75 million||3.66||$42.02 million||$1.69||34.73|
Merit Medical Systems has higher revenue and earnings than Cytocore.
This is a breakdown of recent ratings and price targets for Cytocore and Merit Medical Systems, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Merit Medical Systems||1||0||7||0||2.75|
Merit Medical Systems has a consensus target price of $69.75, indicating a potential upside of 18.82%. Given Merit Medical Systems’ higher probable upside, analysts plainly believe Merit Medical Systems is more favorable than Cytocore.
Merit Medical Systems beats Cytocore on 9 of the 11 factors compared between the two stocks.
MEDITE Cancer Diagnostics, Inc. operates as a medical technology company. It develops, manufactures, and markets molecular biomarkers, medical devices, and consumables for the detection, risk assessment, and diagnosis of cancerous and precancerous conditions and related diseases. The company offers USE 33, an ultrasonic decalcification instrument that automatically runs the process under controlled temperatures; TPC 15 Duo and Trio, a tissue processing instrument; TES 99 and TES Valida cooling units; and M530, A550, M380 microtomes for tissue sectioning. It also provides M630, a freezing microtome; TST44, a robotic multi-staining system; COT 20, a linear staining system; and RCM 9000, ACS 720, and TWISTER robotic coverslippers. In addition, the company develops SoftKit device for the self-collection of a sample that can be evaluated to provide an assessment of the health of the entire female genital tract. It sells its products through direct sales and distributors in the United States, China, Europe, and North Africa. The company serves histology and cytology laboratories associated with hospitals or research institutions, and independent laboratories. MEDITE Cancer Diagnostics, Inc. is headquartered in Orlando, Florida.
About Merit Medical Systems
Merit Medical Systems, Inc. manufactures and markets disposable medical devices for interventional, diagnostic, and therapeutic procedures in cardiology, radiology, oncology, critical care, and endoscopy. The company operates through Cardiovascular and Endoscopy segments. It provides peripheral intervention products, including access, angiography, intervention, and drainage and biopsy for diagnosis and treatment of diseases in peripheral vessels and organs; and cardiac intervention products, such as access, angiography, hemostasis, intervention, and electrophysiology and cardiac rhythm management products to treat various heart conditions. The company also offers cardiovascular and critical care products to treat patients with life-threatening diseases, protect healthcare providers from exposure to bloodborne pathogens, and provide medical devices. In addition, it provides interventional oncology and spine products comprising delivery system, embolotherapy, spine ablation, and vertebral compression fracture products to treat metastatic spinal tumors, liver cancer, uterine fibroids, benign prostatic hyperplasia, vertebral compression fractures, and arteriovenous malformations and hemostatic embolization, as well as breast cancer localization and guidance products for the treatment of breast cancer. Further, the company offers non-vascular stents to treat pulmonary and gastrointestinal diseases; dilation balloons to endoscopically dilate strictures; and kits and accessories for endoscopy and bronchoscopy procedures. Additionally, it provides coated tubes and wires; and microelectromechanical system sensor components. The company sells its products to hospitals and clinic-based physicians, technicians, and nurses through its direct sales force, distributors, original equipment manufacturer partners, or custom procedure tray manufacturers in the United States and internationally. Merit Medical Systems, Inc. was founded in 1987 and is headquartered in South Jordan, Utah.
Receive News & Ratings for Cytocore Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytocore and related companies with MarketBeat.com's FREE daily email newsletter.